Information Provided By: 
Fly News Breaks for October 2, 2015
BMRN, SRPT
Oct 2, 2015 | 08:53 EDT
Wedbush analyst Heather Behanna upgraded Sarepta Therapeutics (SRPT) to Outperform from Neutral and raised her price target for shares to $56 from $31. The new eteplirsen data directly address FDA requests for more information and weigh in favor of the Duchenne muscular dystrophy drug receiving accelerated approval, Behanna tells investors in a research note. The analyst assumes both eteplirsen and BioMarin's (BMRN) competitor drisapersen will be approved and split the market in the U.S.
News For SRPT;BMRN From the Last 2 Days
There are no results for your query SRPT;BMRN
